Skip to main content
. 2023 Feb 27;21(3):158. doi: 10.3390/md21030158

Figure 2.

Figure 2

HIV latency reversing activity and preliminary SARs of OA (1) and its derivates (2–7). (A,B) GFP expression and cell viability in the HIV-1 latent infection model cell 2D10 under the treatments of the indicated concentration of compound 1 or its derivatives (2–7) for 24 h, with prostratin being used as the positive control. Cell viability was labeled as red dots. Black bars represented GFP expression. (C,D) Compound 7 also promoted the HIV-1-LTR-driven luciferase expression in a dose-dependent manner in HeLa-based NH1 and NH2 cells treated for 12 h. (E) Preliminary SARs of compounds 1–7 on HIV latency reversing activity and cytotoxicity. (F) The HeLa-based F1C2 cells stably expressing the FLAG-tagged CDK9 were treated with compound 7 (50 nM) or DMSO for 12 h. Nuclear extracts (NE) and anti-FLAG immunoprecipitates (IP) derived from NE were analyzed by Western blotting for the indicated proteins.